



Systemic Treatment of Advanced Bladder Cancer – Status Update

Guest Editors:

Prof. Helle Pappot

Department of Oncology, Team
Urooncology, Rigshospitalet,
University Hospital of
Copenhagen, Blegdamsvej 9,
2100 Copenhagen, Denmark

Dr. Anders Ullen

1. Patient Area Pelvic Cancer,
Theme Cancer, Karolinska
University Hospital, 17176
Stockholm, Sweden; 2.
Department of Oncology-
Pathology, Karolinska Institute,
17176 Stockholm, Sweden

Deadline for manuscript
submissions:

closed (31 December 2021)

Message from the Guest Editors

Dear Colleagues,

Bladder cancer is diagnosed in more than 400,000 cases annually worldwide, and it represents the sixth most common malignancy in the Western world. Since the mid-80s, systemic treatment of advanced disease has been limited to platinum-based combination chemotherapy, with few treatment options upon progression and with poor overall survival. The very recent advance introducing immune checkpoint inhibitors (ICIs), antibody–drug conjugates (ADCs), and tyrosine kinase inhibitors (TKIs) alongside standard, conventional chemotherapies are, however, changing the paradigm of systemic treatment of advanced UC. ...

Further, the cancer trajectory for a patient with advanced bladder cancer receiving systemic treatment may be influenced by multiple factors, with the outcome dependent on both new biological knowledge as well as optimal supportive care. In this issue, we would like to present the present status of systemic treatment of advanced bladder cancer, covering the spectrum from selection markers to best antineoplastic treatment but also including improved symptom management and issues regarding quality of life in this often vulnerable patient population.





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI